- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02371798
Unilateral Meniere Disease: Can Double Dose Gadolinium and Delayed Imaging Make the Diagnosis?
November 30, 2016 updated by: Patricia Hudgins, Emory University
Diagnosing Endolymphatic Hydrops in Patients With Meniere Disease Using Magnetic Resonance Imaging With Intravenous Gadolinium Administration
The purpose of this research study is to see if magnetic resonance imaging (MRI) with a double dose of contrast, or dye, and delayed imaging with MRI can help to diagnose Meniere Disease.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
Meniere's disease (MD) is a medical condition causing attacks of vertigo, ringing in the ears, hearing loss and often a fullness in the ear.
Currently there is no definitive test to diagnose the problem.
It is believed to be caused by inner ear abnormalities, specifically of an over-collection of lymphatic fluid.The goal of this trial is to determine if an MRI with double dose of IV gadolinium can be diagnostic.
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30308
- Emory University Department of Otolaryngology Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 90 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of unilateral Meniere Disease (MD) per the Committee on Hearing and Equilibrium of the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS)
- Glomerular filtration rate (GFR) > 90 mls/min/1.73 m2
- Creatinine (Cr) level serum < 1.6 mg/dl
Exclusion Criteria:
- Age < 18 years
- Diagnosis of bilateral MD
- History of prior temporal bone surgery
- History of cochlear implant placement
- Pacemaker, cardiac implantable electronic device, shrapnel, aneurysm clips or other metal objects that are prohibited in the MR suite
- GFR < 90 mls/min/1.73m2
- Cr level > 1.6 mg/d
- Lack of IV access
- Contrast allergy to gadolinium agent
- Pregnancy
- Claustrophobia necessitating parenteral anxiolytics
- Patients who are unable to provide informed consent for themselves
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Double dose of Gadopentetate dimeglumine
Subjects with a clinical diagnosis of unilateral Meniere Disease (MD) will undergo 3T MR imaging with a double dose of intravenous (IV) gadolinium contrast injection: 0.2 mmol/kg of Gd-DTPA (Magnevist)
|
IV administration of 0.2 mmol/kg of Gd-DTPA
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Grade of endolymphatic hydrops (EH) in the cochlea and vestibule
Time Frame: 6 hours after intravenous contrast injection
|
Two Certificate of Added Qualifications (CAQ)-certified neuroradiologists will evaluate the MRI findings.
The degree of EH in the vestibule and cochlea will be classified as "none", "grade I" and "grade II," with grade I being defined as mild and grade II being defined as significant.
|
6 hours after intravenous contrast injection
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Patricia Hudgins, MD, Emory University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2015
Primary Completion (ACTUAL)
November 1, 2016
Study Completion (ACTUAL)
November 1, 2016
Study Registration Dates
First Submitted
February 19, 2015
First Submitted That Met QC Criteria
February 19, 2015
First Posted (ESTIMATE)
February 26, 2015
Study Record Updates
Last Update Posted (ESTIMATE)
December 1, 2016
Last Update Submitted That Met QC Criteria
November 30, 2016
Last Verified
November 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00077659
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Meniere Disease
-
Norfolk and Norwich University Hospitals NHS Foundation...University of East Anglia; Ménière's SocietyCompleted
-
Medical University of South CarolinaAmerican Hearing Research Foundation; Cures within Reach FoundationCompletedMeniere DiseaseUnited States
-
Otonomy, Inc.Terminated
-
Beijing Tongren HospitalCompleted
-
Otonomy, Inc.Terminated
-
Alvogen KoreaCompleted
-
Ludwig-Maximilians - University of MunichCompletedMénière's DiseaseGermany
-
University Hospital, BordeauxCompleted
-
University of California, San DiegoAmerican Society of Head and Neck RadiologyCompletedMeniere's DiseaseUnited States
-
Osaka UniversityCompletedMeniere's DiseaseJapan
Clinical Trials on Gadopentetate dimeglumine
-
Bracco Diagnostics, IncCompletedCarotid, Aortic, Renal or Peripheral Artery DiseaseChina
-
BayerCompleted
-
BayerCompleted
-
BayerCompletedMagnetic Resonance ImagingUnited States, Germany
-
BayerCompleted
-
Bracco Diagnostics, IncCompleted
-
BayerCompletedMyocardial InfarctionUnited States, Argentina
-
BayerCompletedFibrosis | Renal Insufficiency | Kidney FailureUnited States